IGF2/IR/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma - Université de Rennes Access content directly
Journal Articles Clinical Cancer Research Year : 2018

IGF2/IR/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma

Abstract

Cholangiocarcinoma (CCA) is a desmoplastic tumor of the biliary tree in which epidermal growth factor receptor (EGFR) is overexpressed and contributes to cancer progression. Although, EGFR has been envisaged as a target for therapy, treatment with tyrosine kinase inhibitors (TKI) such as erlotinib did not provide therapeutic benefit in patients with CCA, emphasizing the need to investigate resistance mechanisms against EGFR inhibition.

Dates and versions

hal-01808092 , version 1 (05-06-2018)

Identifiers

Cite

Javier Vaquero, Cindy Lobe, Sylvana Tahraoui, Audrey Clapéron, Martine Mergey, et al.. IGF2/IR/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma. Clinical Cancer Research, 2018, 24 (17), pp.4282-4296. ⟨10.1158/1078-0432.CCR-17-3725⟩. ⟨hal-01808092⟩
97 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More